Keywords: XOMA, UCB, Cimzia, Royalty rights

XOMA sells royalty rights on Cimzia for $4 million

Article | 20 August 2010

California, USA-based therapeutic antibody firm XOMA (Nasdaq: XOMA) says it has sold its royalty interest in Cimzia (certolizumab pegol), which ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

XOMA Corp

UCB

Go to company listing

Related Drugs

Cimzia

Go to drug listing